骨关节炎与类风湿关节炎患者非甾体抗炎药安全性差异:一项随机临床试验
该双盲随机对照试验纳入24,081例心血管风险中高的骨关节炎或类风湿关节炎患者,比较塞来昔布与布洛芬或萘普生的长期安全性。在骨关节炎亚组中,塞来昔布较布洛芬显著降低主要心血管不良事件风险(HR 0.84),但类风湿关节炎亚组中对比无显著差异。总体而言,塞来昔布在批准剂量下心血管、胃肠和肾脏不良事件风险与布洛芬或萘普生相似或更低。
要点
- 骨关节炎患者中塞来昔布较布洛芬显著降低主要心血管不良事件风险(HR 0.84,95%CI 0.72-0.99)。
- 类风湿关节炎患者中塞来昔布与布洛芬或萘普生的主要心血管不良事件风险无显著差异。
- 骨关节炎患者中塞来昔布较布洛芬和萘普生显著降低胃肠事件风险;类风湿关节炎患者中对比无显著差异。
核心结论
- 在骨关节炎和类风湿关节炎患者中,批准剂量的塞来昔布治疗与布洛芬或萘普生相比,心血管、胃肠和肾脏不良事件风险相似或更低。
研究设计与样本
- 国际多中心双盲随机对照试验,纳入24,081例心血管风险中高、患有骨关节炎或类风湿关节炎的患者。
- 干预为塞来昔布100-200 mg每日两次、布洛芬600-800 mg每日三次或萘普生375-500 mg每日两次。
- 主要结局为主要心血管不良事件、胃肠事件、肾脏事件的首发及死亡。
主要发现
- 骨关节炎亚组中,塞来昔布较布洛芬显著降低主要心血管不良事件风险(HR 0.84,95%CI 0.72-0.99),塞来昔布与萘普生对比无显著差异。
- 类风湿关节炎亚组中,塞来昔布对比布洛芬和萘普生的主要心血管不良事件HR分别为1.06(95%CI 0.69-1.63)和1.22(95%CI 0.78-1.92)。
- 骨关节炎亚组中,塞来昔布对比布洛芬的胃肠事件HR为0.68(95%CI 0.51-0.91),对比萘普生的HR为0.73(95%CI 0.55-0.98)。
- 类风湿关节炎亚组中,塞来昔布对比布洛芬和萘普生的胃肠事件HR分别为0.48(95%CI 0.22-1.07)和0.54(95%CI 0.24-1.24)。
- 骨关节炎患者中,塞来昔布对比布洛芬的肾脏事件HR为0.58(95%CI 0.40-0.82);类风湿关节炎患者中,塞来昔布对比萘普生显著降低死亡风险(HR 0.47,95%CI 0.25-0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA). METHODS: A total of 24,081 patients with OA or RA who had a moderate or high risk for CV disease were enrolled internationally into a double-blind randomized controlled trial. Interventions included celecoxib at a dosage of 100-200 mg twice daily, ibuprofen at a dosage of 600-800 mg 3 times daily, or naproxen at a dosage of 375-500 mg twice daily. The main outcomes were the first occurrence of a major adverse CV event, GI event, or renal event, and mortality. RESULTS: In the subgroup of patients with OA, the risk of a major adverse CV event was significantly reduced when celecoxib was compared with ibuprofen (hazard ratio [HR] 0.84, 95% confidence interval [95% CI] 0.72-0.99), but no significant difference was observed when celecoxib was compared with naproxen. In the RA subgroup, comparisons of celecoxib versus ibuprofen and celecoxib versus naproxen for the risk of major adverse CV events revealed HRs of 1.06 (95% CI 0.69-1.63) and 1.22 (95% CI 0.78-1.92), respectively. In the OA subgroup, comparisons of celecoxib versus ibuprofen for the risk of GI events showed an HR of 0.68 (95% CI 0.51-0.91), and a comparison of celecoxib versus naproxen showed an HR of 0.73 (95% CI 0.55-0.98). Duplicate comparisons in patients with RA revealed HRs of 0.48 (95% CI 0.22-1.07) and 0.54 (95% CI 0.24-1.24), respectively. In patients with OA, a comparison of celecoxib versus ibuprofen for the risk of renal events showed an HR of 0.58 (95% CI 0.40-0.82). In patients with RA, celecoxib treatment was associated with significantly lower mortality compared with naproxen treatment (HR 0.47, 95% CI 0.25-0.88). CONCLUSION: Treatment with celecoxib at approved dosages conferred a similar or lower risk of CV, GI, and renal adverse events compared with treatment with ibuprofen or naproxen in patients with OA and patients with RA.
引用
- Solomon DH, Husni ME, Wolski KE, et al. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018. PMID: 29266879. doi:10.1002/art.40400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。